- Home
- ACAD vs BATRA Comparison
ACAD vs BATRA Comparison
Compare ACAD & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- BATRA
- Stock Information
- Founded
- ACAD 1993
- BATRA 1991
- Country
- ACAD United States
- BATRA United States
- Employees
- ACAD N/A
- BATRA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- BATRA Broadcasting
- Sector
- ACAD Health Care
- BATRA Industrials
- Exchange
- ACAD Nasdaq
- BATRA Nasdaq
- Market Cap
- ACAD 2.8B
- BATRA 2.6B
- IPO Year
- ACAD 2004
- BATRA N/A
- Fundamental
- Price
- ACAD $17.57
- BATRA $40.28
- Analyst Decision
- ACAD Buy
- BATRA Strong Buy
- Analyst Count
- ACAD 19
- BATRA 2
- Target Price
- ACAD $26.17
- BATRA $53.50
- AVG Volume (30 Days)
- ACAD 4.3M
- BATRA 48.3K
- Earning Date
- ACAD 02-25-2025
- BATRA 02-26-2025
- Dividend Yield
- ACAD N/A
- BATRA N/A
- EPS Growth
- ACAD N/A
- BATRA N/A
- EPS
- ACAD 0.78
- BATRA N/A
- Revenue
- ACAD $929,236,000.00
- BATRA $678,378,000.00
- Revenue This Year
- ACAD $36.78
- BATRA $10.38
- Revenue Next Year
- ACAD $8.19
- BATRA $5.23
- P/E Ratio
- ACAD $22.63
- BATRA N/A
- Revenue Growth
- ACAD 47.06
- BATRA 5.31
- 52 Week Low
- ACAD $14.15
- BATRA $38.90
- 52 Week High
- ACAD $29.29
- BATRA $46.65
- Technical
- Relative Strength Index (RSI)
- ACAD 52.06
- BATRA 47.58
- Support Level
- ACAD $16.61
- BATRA $39.32
- Resistance Level
- ACAD $18.23
- BATRA $40.69
- Average True Range (ATR)
- ACAD 0.74
- BATRA 0.64
- MACD
- ACAD -0.05
- BATRA 0.06
- Stochastic Oscillator
- ACAD 36.59
- BATRA 55.87
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
About BATRA Atlanta Braves Holdings Inc. Series A
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include, baseball which generates key revenue, and mixed-use development.